Marker Therapeutics Inc (MRKR)

[4fatcat4]

I doubt that the millions that would die from cancer in the next 8 years would agree with your assessment that it is a bargain.

With TPIV 100/200 successes in trials, along with orphan and fast track designations, should skyrocket share price in normal circumstances. Add the Polystart vaccines and data from MultiTAA trials and we have thus far the most innovative and effective treatments for both the cure and prevention of various cancers.

What isn't normal, eerily resembling the pancreatic fiasco, is the presence of 5+m short interest that once again defies logic in shorting a stock especially with the success MRKR treatments continue to prove. The Fall took the market share down to 200m, severely undervalued for it's successes, so what do shorters have to gain this time around?

If Peter comes out with a mundane, so-so evaluation that can be downplayed as just another treatment years away from FDA approval, then he should be fired on the spot. Both Polystart and MultiTAA should receive fast track and/or orphan designations also, and I only hope the cc extrapolates their successes to that end.

Bottom line, I don't trust Peter and don't trust 5m short shares, not after the Fall. What I do trust, based simply on trials thus far, is the science developed by TPIV and now MRKR to continue to prove that it is gamechanging in cancer treatments.